Trends, Predictors, and Outcomes of 30-Day Readmission With Heart Failure After Transcatheter Aortic Valve Replacement: Insights From the US Nationwide Readmission Database.
Salman Zahid,Mian Tanveer Ud Din,Muhammad Zia Khan,Devesh Rai,Waqas Ullah,Alejandro Sanchez‐Nadales,Ahmed Elkhapery,Muhammad Usman Khan,Andrew M. Goldsweig,Atul Singla,Greg Fonarrow,Sudarshan Balla
DOI: https://doi.org/10.1161/JAHA.121.024890
IF: 6.106
2022-08-06
Journal of the American Heart Association
Abstract:BACKGROUND Data on trends, predictors, and outcomes of heart failure (HF) readmissions after transcatheter aortic valve replacement (TAVR) remain limited. Moreover, the relationship between hospital TAVR discharge volume and HF readmission outcomes has not been established. METHODS AND RESULTS The Nationwide Readmission Database was used to identify 30‐day readmissions for HF after TAVR from October 1, 2015, to November 30, 2018, using International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ) codes. A total of 167 345 weighted discharges following TAVR were identified. The all‐cause readmission rate within 30 days of discharge was 11.4% (19 016). Of all the causes of 30‐day rehospitalizations, HF comprised 31.4% (5962) of all causes. The 30‐day readmission rate for HF did not show a significant decline during the study period ( P trend =0.06); however, all‐cause readmission rates decreased significantly ( P trend =0.03). HF readmissions were comparable between high‐ and low‐volume TAVR centers. Charlson Comorbidity Index >8, length of stay >4 days during the index hospitalization, chronic obstructive pulmonary disease, atrial fibrillation, chronic HF, preexisting pacemaker, complete heart block during index hospitalization, paravalvular regurgitation, chronic kidney disease, and end‐stage renal disease were independent predictors of 30‐day HF readmission after TAVR. HF readmissions were associated with higher mortality rates when compared with non‐HF readmissions (4.9% versus 3.3%; P <0.01). Each HF readmission within 30 days was associated with an average increased cost of $13 000 more than for each non‐HF readmission. CONCLUSIONS During the study period from 2015 to 2018, 30‐day HF readmissions after TAVR remained steady despite all‐cause readmissions decreasing significantly. All‐cause readmission mortality and HF readmission mortality also showed a nonsignificant downtrend. HF readmissions were comparable across low‐, medium‐, and high‐volume TAVR centers. HF readmission was associated with increased mortality and resource use attributed to the increased costs of care compared with non‐HF readmission. Further studies are needed to identify strategies to decrease the burden of HF readmissions and related mortality after TAVR. Nonstandard Abbreviations and Acronyms NRD Nationwide Readmission Database PPM preexisting permanent pacemaker TAVR transcatheter aortic valve replacement Clinical Perspective What Is New? At 30 days after transcatheter aortic valve replacement, 1 in 3 readmissions is attributed to heart failure and is associated with higher readmission mortality rates compared with non–heart failure readmission. What Are the Clinical Implications? High comorbidity burden, length of stay >4 days during the index hospitalization, anemia, atrial fibrillation, paravalvular regurgitation, history of heart failure, preexisting pacemaker, complete heart block during the index hospitalization, chronic kidney disease, and end‐stage renal disease are predictors of 30‐day heart failure readmission. Since the first‐in‐human use of transcatheter aortic valve replacement (TAVR) in 2002, TAVR has emerged as the treatment of choice for severe aortic stenosis across the spectrum of surgical risk. 1 , 2 , 3 With the rapid advancements in device technology, expansion to lower risk patient groups, increased operator volume, and site experience, TAVR outcomes, including readmission rates, have improved significantly in recent years. 4 , 5 Although noncardiac readmissions after TAVR are more common, among cardiac causes of readmissions, heart failure (HF) remains one of the most common culprits. 6 , 7 HF readmissions after TAVR have been associated with significant mortality, morbidity, and health system resource use. 7 , 8 Although all‐cause readmission rates after TAVR have decreased, the trend of HF readmission has not been established. 5 , 6 Similarly, previous studies have reported that increased site TAVR volume may be -Abstract Truncated-
cardiac & cardiovascular systems